Sequential treatment with AT-101 enhances cisplatin chemosensitivity in human non-small cell lung cancer cells through inhibition of apurinic/apyrimidinic endonuclease 1-activated IL-6/STAT3 signaling pathway

Sequential treatment with AT-101 enhances cisplatin chemosensitivity in human non-small cell lung cancer cells through inhibition of apurinic/apyrimidinic endonuclease 1-activated IL-6/STAT3 signaling pathway

Tao Ren,1,2,* Jinlu Shan,1,* Yi Qing,1 Chengyuan Qian,1 Qing Li,1 Guoshou Lu,1 Mengxia Li,1 Chongyi Li,1 Yu Peng,1 Hao Luo,1 Shiheng Zhang,1 Weiwei Zhang,1 Dong Wang,1 Shu-Feng Zhou3 1Cancer Center, Daping Hospital and Research Institute of Surgery, Third Military Medical University, Chongqing, Pe...

Full description

Bibliographic Details
Main Authors: Ren T, Shan J, Qing Y, Qian C, Li Q, Lu G, Li M, Li C, Peng Y, Luo H, Zhang S, Zhang W, Wang D, Zhou SF
Format: Article
Language:English
Published: Dove Medical Press 2014-12-01
Series:Drug Design, Development and Therapy
Online Access:http://www.dovepress.com/sequential-treatment-with-at-101-enhances-cisplatin-chemosensitivity-i-peer-reviewed-article-DDDT

Internet

http://www.dovepress.com/sequential-treatment-with-at-101-enhances-cisplatin-chemosensitivity-i-peer-reviewed-article-DDDT

Similar Items